Y491 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸ð³ë¾Æ¹Î-¿Á½Ãµ¥À̽º ¾ïÁ¦¼º Ç׿ì¿ïÁ¦ | Monoamine-oxidase-inhibitor antidepressants causing adverse effects in therapeutic use |
|
Y492 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Ç׿ì¿ïÁ¦ | Other and unspecified antidepressants causing adverse effects in therapeutic use |
|
Y493 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Æä³ëµð¾ÆÁø Ç×Á¤½Åº´ ¾àÁ¦ ¹× ½Å°æÀÌ¿ÏÁ¦ | Phenothiazine antipsychotics and neuroleptics causing adverse effects in therapeutic use |
|
Y494 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºÎƼ·ÎÆä³í ¹× Áö¿Á»êƾ ½Å°æÀÌ¿ÏÁ¦ | Butyrophenone and thioxanthene neuroleptics causing adverse effects in therapeutic use |
|
Y495 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç×Á¤½Åº´¾àÁ¦ ¹× ½Å°æÀÌ¿ÏÁ¦ | Other antipsychotics and neuroleptics causing adverse effects in therapeutic use |
|
Y496 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ȯ°¢Á¦ | Psychodysleptics [hallucinogens] causing adverse effects in therapeutic use |
|
Y497 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ³²¿ëÀÇ ÀáÀ缺ÀÌ ÀÖ´Â Á¤½ÅÈïºÐÁ¦ | Psycostimulants with abuse potential causing adverse effects in therapeutic use |
|
Y498 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ Á¤½ÅÀÛ¿ë¾à¹° | Other psychotropic drugs, NEC causing adverse effects in therapeutic use |
|
Y499 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ Á¤½ÅÀÛ¿ë¾à¹° | Psychotropic drug, unspecified causing adverse effects in therapeutic use |
|
Y50 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ÁßÃ߽Űæ°èÅë ÈïºÐÁ¦ | Central nervous system stimulants, NEC causing adverse effects in therapeutic use |
|
Y500 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °¢¼ºÁ¦ | Analeptics causing adverse effects in therapeutic use |
|
Y501 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾ÆÆí¼ö¿ëü±æÇ×Á¦ | Opioid reactor antagonists causing adverse effects in therapeutic use |
|
Y502 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¸ÞÆ¿»êƾ | Methylxanthines, NEC causing adverse effects in therapeutic use |
|
Y502 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ä«ÆäÀÎ | Caffeine causing adverse effects in therapeutic use |
|
Y508 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ÁßÃ߽Űæ°èÅë ÈïºÐÁ¦ | Other central nervous system stimulants causing adverse effects in therapeutic use |
|
Y509 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ÁßÃ߽Űæ°èÅë ÈïºÐÁ¦ | Central nervous system stimulant, unspecified causing adverse effects in therapeutic use |
|
Y51 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ÀÚÀ²½Å°æ°èÅë¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦ | Drugs primarily affecting the autonomic nervous system causing adverse effects in therapeutic use |
|
Y510 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×Äݸ°¿¡½ºÆ®·¹À̽ºÁ¦ | Anticholinesterase agents causing adverse effects in therapeutic use |
|
Y511 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ºÎ±³°¨½Å°æÀÛ¿ëÁ¦[Äݸ°Á¦] | Other parasympathomimetics[cholinergics] causing adverse effects in therapeutic use |
|
Y512 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ½Å°æÀýÂ÷´ÜÁ¦ | Ganglionic blocking drugs, NEC causing adverse effects in therapeutic use |
|